HomeCompareABALX vs ABBV

ABALX vs ABBV: Dividend Comparison 2026

ABALX yields 1.45% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $84.8K in total portfolio value
10 years
ABALX
ABALX
● Live price
1.45%
Share price
$36.31
Annual div
$0.53
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.9K
Annual income
$0.14
Full ABALX calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — ABALX vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABALXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABALX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABALX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABALX
Annual income on $10K today (after 15% tax)
$122.90/yr
After 10yr DRIP, annual income (after tax)
$0.12/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $21,866.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABALX + ABBV for your $10,000?

ABALX: 50%ABBV: 50%
100% ABBV50/50100% ABALX
Portfolio after 10yr
$62.3K
Annual income
$12,862.93/yr
Blended yield
20.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ABALX
No analyst data
Altman Z
2168.7
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABALX buys
0
ABBV buys
0
No recent congressional trades found for ABALX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABALXABBV
Forward yield1.45%3.12%
Annual dividend / share$0.53$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$19.9K$104.7K
Annual income after 10y$0.14$25,725.73
Total dividends collected$145.00$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ABALX vs ABBV ($10,000, DRIP)

YearABALX PortfolioABALX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,772$72.29$11,559$438.51$787.00ABBV
2$11,563$36.39$13,494$640.86$1.9KABBV
3$12,390$18.25$15,951$945.97$3.6KABBV
4$13,267$9.14$19,152$1,413.89$5.9KABBV
5$14,200$4.57$23,443$2,146.38$9.2KABBV
6$15,196$2.29$29,391$3,321.96$14.2KABBV
7$16,261$1.14$37,948$5,265.87$21.7KABBV
8$17,400$0.57$50,795$8,596.74$33.4KABBV
9$18,618$0.29$71,034$14,549.41$52.4KABBV
10$19,922$0.14$104,715$25,725.73$84.8KABBV

ABALX vs ABBV: Complete Analysis 2026

ABALXStock

The investment seeks conservation of capital, current income and long-term growth of capital and income. The fund uses a balanced approach to invest in a broad range of securities, including common stocks and investment-grade bonds. It also invests in securities issued and guaranteed by the U.S. government and by federal agencies and instrumentalities. In addition, the fund may invest a portion of its assets in common stocks, most of which have a history of paying dividends, bonds and other securities of issuers domiciled outside the United States.

Full ABALX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ABALX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABALX vs SCHDABALX vs JEPIABALX vs OABALX vs KOABALX vs MAINABALX vs JNJABALX vs MRKABALX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.